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Abstract: A double-blind, randomized, active placebo-controlled pilot study
was conducted to examine safety and efficacy of lysergic acid diethylamide
(LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-
threatening diseases. Treatment included drug-free psychotherapy sessions
supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart.
The participants received either 200 Kg of LSD (n = 8) or 20 Kg of LSD with
an open-label crossover to 200 Kg of LSD after the initial blinded treatment
was unmasked (n = 4). At the 2-month follow-up, positive trends were found
via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety ( p =
0.033) with an effect size of 1.1, and state anxiety was significantly reduced
( p = 0.021) with an effect size of 1.2, with no acute or chronic adverse effects
persisting beyond 1 day after treatment or treatment-related serious adverse
events. STAI reductions were sustained for 12 months. These results indicate
that when administered safely in a methodologically rigorous medically su-
pervised psychotherapeutic setting, LSD can reduce anxiety, suggesting that
larger controlled studies are warranted.
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LSD is a semisynthetic compound first synthesized in 1938 bySwiss chemist Albert Hofmann at Sandoz laboratories in Basel.
Its psychoactive effects were discovered in 1943 (Hofmann, 1979).
LSD was named Delysid and distributed by Sandoz as an investiga-
tional drug for psychiatric research (Hintzen and Passie, 2010). LSD-
assisted psychotherapy was primarily explored for treating alcoholism,
neurosis, and psychosomatic disorders (Abramson, 1967).
LSD in oral doses of more than 100 Kg produces vivid
psychosensory changes, including increased sensory perception,
illusionary changes of perceived objects, synesthesia, and enhanced
mental imagery. Affectivity is intensified. Thoughts are accelerated,
with their scope usually broadened including new associations
and modified interpretation and meanings of relationships and ob-
jects. Hypermnesia and enhanced memory processes typically occur.
Ego identification is usually weakened. The general state of con-
sciousness can be compared to a daydream, but with pronounced
affectivity and enhanced production of inner stimuli (Grof, 1975;
Hintzen and Passie, 2010). LSD has been described as a ‘‘non-specific
amplifier of the unconscious’’ (Grof, 1975). These effects last for 6 to
9 hours and can be used to support and enhance psychotherapeutic
processing.
LSD’s effects on brain functioning are complex and not fully
understood. LSD influences diverse neurotransmitter systems (Nichols,
2004; Passie et al., 2008), but its psychosensory effects are mainly
mediated by activation of the 5-HT2A receptors, with significant
modulation by 5-HT2C and 5-HT1A receptors (Nichols, 2004;
Vollenweider, 1998). No neuroimaging studies have been conducted
with LSD, whereas neuroimaging studies with the LSD-related
substances psilocybin (Carhart-Harris et al., 2012; Gouzoulis-
Mayfrank et al., 1999; Vollenweider et al., 1997) and dimethyl-
tryptamine (de Araujo et al., 2012; Riba et al., 2006) have yielded
inconclusive results, presumably because of methodological chal-
lenges. The few congruent results throughout different studies are
activation of the right hemisphere, altered thalamic functioning, and
increased activity in paralimbic structures and the frontal cortex.
The development of psychotherapy with psychedelic drugs
started in the 1950s with two approaches. The ‘‘psycholytic’’ method
used lower doses and frequent sessions to enhance the standard
psychotherapeutic process (Leuner, 1981). The ‘‘psychedelic’’ method
used higher doses in fewer sessions to induce a mystical experience
and moments of intense catharsis (Grof, 1980), enabling participants
to work through and integrate difficult feelings and situations, thereby
reducing anxiety and depression (Grob et al., 2011; Grof and Halifax,
1978; Kurland, 1985). After a trial in 1963 found LSD (combined with
counseling) to reduce anxiety, depression, and pain in advanced-stage
cancer patients (Kast and Collins, 1964), it was followed by studies
with more than 100 advanced-stage cancer patients that established the
approach and demonstrated safety and promising results (Kurland,
1985; Yensen and Dryer, 1992). The psychedelic method was most
commonly used in patients with terminal cancer (Kurland, 1985;
Pahnke et al., 1969). These studies were difficult to design as placebo-
controlled studies for ethical reasons and difficult to successfully blind
because of the psychoactive intervention.
Research into LSD-assisted psychotherapy rapidly came to a
halt when LSD was made illegal in the United States in 1966 because
of increased nonmedical use (Grinspoon and Bakalar, 1997). Some LSD-
assisted psychotherapy continued in Czechoslovakia, the Netherlands,
and Germany during the 1970s (Leuner, 1981) and in Switzerland from
1988 to 1993 (Gasser, 1996). Recently, a small pilot study of psilocybin-
assisted psychotherapy with advanced-stage cancer patients in the
United States obtained promising results (Grob et al., 2011), with
several additional studies currently in process at Johns Hopkins and
New York University. This is the first controlled study of LSD-assisted
psychotherapy in more than 40 years.
End-of-life issues, including pain management and palliative
care, are increasingly recognized as significant public health concerns
(Howell et al., 2010; Schweiz Krebsliga, 2005). The target popula-
tion of this study was chosen because patients with life-threatening
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illnesses often fail to obtain satisfactory emotional relief from cur-
rently available treatment options. Anxiety, depression, chronic pain, as
well as unresolved family and relationship issues can become serious
problems for these individuals. The present LSD study was designed
to evaluate previous findings applying current research methodology.
METHODS
Ethics
This phase 2 double-blind, active placebo-controlled, ran-
domized clinical trial (Multidisciplinary Association for Psyche-
delic Studies, 2007) was approved by the Ethics Committee of the
Canton of Aargau, Swissmedic, the Swiss Federal Office for Public
Health (Bundesamt fuer Gesundheit [Swiss Ministry of Health]), and
the US Food and Drug Administration (Investigational New Drug no.
101,825) and was conducted in accordance with Good Clinical Prac-
tices. After complete description of the study to all participants, written
informed consent was obtained.
Participants
The participants were recruited through general information
about the study reported in media, by flyers, presentations in hospitals
or cancer support groups, or referral from other physicians. Of 70
participants who were evaluated for eligibility by telephone or
e-mail, 20 were further screened in person, and 12 were enrolled
in this study (Fig. 1). Eleven of the 12 subjects had no prior ex-
perience with LSD. Individuals with current alcohol or drug de-
pendence (except caffeine or nicotine); primary psychotic, bipolar
I affective, or dissociative disorders; and neurocognitive impair-
ment and women who were pregnant or nursing were excluded
from this study. All participants reported a score of greater than 40
on either the state or the trait scale of the Spielberger State-Trait
Anxiety Inventory (STAI; Spielberger et al., 1970). According to
the Structured Clinical Interview for Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (SCID), diagnosis
(First et al., 2002), half of the subjects were diagnosed with gen-
eralized anxiety disorder (GAD). Neither the SCID’s five items
about GAD nor criterion E for GAD in the Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition, differentiates
between anxiety typically seen with GAD and a reaction to a life-
threatening disease (and its consequences). Therefore, even though
the SCID generates a diagnosis of GAD, this does not mean that
the subjects had the conventional pattern of psychopathology
usually associated with GAD. Recruitment took place from 2007
FIGURE 1. Consolidated standards of reporting trials LSD/anxiety flow diagram.
Gasser et al. The Journal of Nervous and Mental Disease & Volume 00, Number 00, Month 2014
2 www.jonmd.com * 2014 Lippincott Williams & Wilkins
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
to 2011 until all planned participants were enrolled, and study visits
were completed from 2008 to 2012. Table 1 summarizes participant
demographic characteristics.
Set
The psychotherapeutic method used in this study was a con-
tinuous process lasting several months. Two preparatory psycho-
therapy sessions served to discuss the participant’s history, social
situation, personality, health, mind-set, and emotional situation, also
known by the term set (Zinberg, 1986). These also served to explain
the action of LSD and structure of the setting, answer questions, and
build therapeutic alliance.
Setting
The physical environment within which the experimental
sessions took place was a safe, quiet, and pleasant room in a private
practice office. The participant was advised to lie on a mattress on the
floor or sit comfortably on a chair. Other than going to the bathroom,
the participants remained in the treatment room for the entire 8-hour
experimental session and overnight with an attendant nearby.
Experimental Drug
LSDwas supplied as free base byLipomed (Arlesheim, Switzerland).
Capsules consisting of 200 Kg (experimental dose) and 20 Kg of
LSD (active placebo) were prepared by Bichsel Laboratories (In-
terlaken, Switzerland). Quality control, randomization, and blinding
were performed by R. Brenneisen, PhD, at the Department of Clin-
ical Research, University of Bern, Switzerland. Capsules were of
identical size, color, and shape and were bottled in sequentially num-
bered containers.
Experimental Intervention
The primary intervention consisted of two full-day experimental
sessions scheduled 2 to 3 weeks apart with a male/female co-therapist
TABLE 1. Participant Demographic Characteristics
Characteristic Categories
Experimental
Dose Group
Active Placebo
Group Total
n = 8 n = 3 n = 11
Sex Female 3 37.5% 1 33.3% 4 36.4%
Male 5 62.5% 2 66.7% 7 63.6%
Age, mean (SD) Range 39Y64 yrs 49.6 8.5 57.4 9.9 51.7 9.1
Marital status Single 1 12.5% 1 33.3% 2 18.2%
Married/living with partner 4 50% 2 66.7% 6 54.5%
Divorced/separated 3 37.5% 0 0% 3 27.3%
Work status On disability 1 12.5% 0 0% 1 9.1%
Fit for limited employment 2 25% 2 66.7% 4 36.4%
Working full time 4 50% 0 0% 4 36.4%
Retired 1 12.5% 1 33.3% 2 18.2%
Spiritual orientation Protestant 1 12.5% 1 33.3% 2 18.2%
Roman Catholic 0 0% 1 33.3% 1 9.1%
Buddhist 1 12.5% 0 0% 1 9.1%
Not religious 6 75% 1 33.3% 7 63.6%
History of substance abuse/dependency Alcohol 0 0% 0 0% 0 0%
Illegal drugs 0 0% 0 0% 0 0%
History of suicidal tendencies None 8 100% 1 33.3% 9 81.8%
Mild 0 0% 2 66.7% 2 18.2%
Life-threatening illness Metastatic breast carcinoma 3 37.5% 1 33.3% 4 36.4%
Metastatic gastric carcinoma 2 25% 0 0% 2 18.2%
Plasmocytoma 1 12.5% 0 0% 1 9.1%
Non-Hodgkin’s lymphoma 0 0% 1 33.3% 1 9.1%
Celiac disease 0 0% 1 33.3% 1 9.1%
Parkinson’s disease 1 12.5% 0 0% 1 9.1%
Bechterew’s disease 1 12.5% 0 0% 1 9.1%
Comorbid disorder GAD 5 62.5% 1 33.3% 6 54.5%
Major depression 6 75% 1 33.3% 7 63.6%
Reactive depression 0 0% 1 33.3% 1 9.1%
Dysthymia 1 12.5% 1 33.3% 2 18.2%
PTSD 1 12.5% 0 0% 1 8.3%
Panic disorder 2 25% 1 33.3% 3 27.3%
Social phobia 1 12.5% 0 0% 1 8.3%
Prestudy medications Antidepressant 3 37.5% 1 33.3% 4 36.4%
Antianxiety 1 12.5% 2 66.7% 3 27.3%
Pain relief 3 37.5% 2 66.7% 5 45.4%
None 3 37.5% 1 33.3% 4 36.4%
PTSD indicates posttraumatic stress disorder.
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team, embedded within an ongoing process of drug-free psychother-
apy sessions for preparatory and integrative purposes.
The participants were randomly assigned to the experimental
dose groups, receiving either an oral dose of 200 Kg of LSD (n = 8) or
an active placebo of 20Kg of LSD (n = 4). The experimental dosewas a
moderate amount expected to produce the full spectrum of a typical
LSD experience, without fully dissolving normal ego structures. The
20-Kg dose of LSD was chosen as an active placebo to produce short-
lived, mild, and detectable LSD effects that would not substantially
facilitate a therapeutic process. The participant, the co-therapists, and
the independent rater were blinded to condition assignment.
The participants were required to taper off of antidepressants
and antianxiety medications, to avoid alcohol and recreational drugs
for 24 hours before, and to abstain from driving for 24 hours after
the experimental sessions. On the morning of the experimental ses-
sions, the participants arrived at the office for a short discussion
about their current mood and mental state and a urine drug test (Drug
Screen Multi5A: amphetamine, cocaine, morphine, methamphetamine,
tetrahydrocannabinole; nal von minden GmbH, Moers/Germany). If the
subjects tested positive, the session would have been postponed, but this
did not occur. After LSD administration, the participants were instructed
to focus their awareness and mindful attention inward to follow their
personal process of perception, emotion, and cognition. Lengthy dis-
cussions between the participants and the co-therapists were discouraged
during the acute effects of the LSD. Approximately two thirds of each
LSD-assisted experimental session was focused inward with music
played to deepen self-awareness and facilitate emotional processing, and
one third contained brief conversations. The therapeutic session ended
after 8 hours, when the acute effects had subsided, followed by a
brief review of the day’s experiences.
After each experimental session, three drug-free psychother-
apy sessions lasting 60 to 90 minutes took place, during which the
participant’s experiences were reviewed for integration and deepening
the therapeutic process. Two months after the second experimental
session, a follow-up evaluation was completed, and the treatment pe-
riod was finished by breaking the blind for each individual. The par-
ticipants who received the active placebo could cross over to an
identical but open-label treatment with 200 Kg of LSD. A long-term
follow-up evaluation was conducted 12 months after the last experi-
mental session with LSD in either the blinded portion of the study or
the open-label crossover.
Assessments
A nurse collected heart rate and blood pressure measurements
during experimental sessions. After two experimental sessions, a
follow-up physical examination was performed by the participant’s
physician. Throughout the study, adverse events (AEs) were col-
lected, and related AEs were recorded during experimental sessions
and at the integrative session on the day after. The related AEs
contained both AEs that were disturbing for the participant and those
that belong to the mode of action of LSD (e.g., visual patterns).
Concomitant medications used to treat anxiety, depression, and pain
before the study and in between experimental sessions were docu-
mented. The subjects tapered off of these types of concomitant medi-
cations approximately five half-lives before each experimental session.
Psychometric Measures
The independent rater, an experienced clinical psychologist,
conducted the SCID to establish psychiatric diagnoses at screening
(Wittchen et al., 1997). The STAI Form X, a widely used self-report
instrument for assessing state and trait anxiety in adults, served as the
primary outcome measure of anxiety symptoms. Secondary outcome
measures included the European Cancer Quality of Life Questionnaire
30-item version 1.0 (EORTC-QLQ-30; Aaronson et al., 1993), the
SCL-90-R (Schmitz et al., 2000), and the Hospital Anxiety and De-
pression Scale (HADS; Herrmann-Lingen et al., 2011). Outcome
measures were completed at baseline, 1 week after experimental ses-
sions, 2-month follow-up, and 12-month follow-up. The participants
completed a daily dairy on changes in medication, adverse effects of
LSD or medications, and pain using the Visual Analog Pain Scale.
After each experimental session, the State of Consciousness Ques-
tionnaire was completed (Griffiths et al., 2006).
Statistical Analysis
The statistical software Statistical Package for the Social Sci-
ences for Windows, version 18.0 (IBM Corp, New York), was used.
FIGURE 2. Study outcomes. State and trait anxiety scores in the LSD and placebo group. Values are mean T SEM of changes from
baseline in eight subjects in the LSD group and three subjects in the placebo group. Measures were obtained before the first
treatment session (baseline), 1 week after the first treatment (post 1 LSD), 1 week after the second treatment (LSD 2), and at
follow-up after 2 months. At 2 months, state anxiety scores were significantly lower in the LSD group compared with the placebo
group. The crossover group (n = 3) shows a positive trend of STAI state and trait score reduction. At 12-month follow-up, the state
and trait values remain stable compared with the 2-month follow-up.
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Repeated-measures analysis of variance (ANOVA) was used to test for
significant changes in anxiety from baseline to subsequent post-
treatment measurements. STAI trait and STAI state were analyzed in
separate ANOVAs. To account for multiplicity, the alpha level indi-
cating significance was adjusted to 0.025 (two tailed). Effect sizes were
estimated using Cohen’s d techniques. Results of the 12-month follow-up
were compared with those of the 2-month follow-up with paired t-tests.
Secondary outcome measures conducted for exploratory purposes were
not used for significance testing to reduce multiplicity.
We were unable to obtain results for two subjects (one ex-
perimental dose, one active placebo) from the assessment conducted
1 week after the second experimental session because of intervening
cancer treatments. To avoid substantially reducing the sample size
because of missing data, the assessment 1 week after the second
experimental session was dropped for all subjects from analysis of
outcomes. One active placebo participant was excluded from anal-
ysis after completing all study procedures because of a correction in
the diagnosis of the qualifying disease state, which no longer satis-
fied the inclusion criteria.
RESULTS
Clinical Response
For STAI trait, Mauchly’s Test of Sphericity was not signifi-
cant ( p = 0.824) and sphericity was assumed. No significant differ-
ence was found ( p = 0.261) between group mean scores at baseline.
The visit  group interaction testing for differences between the
groups produced p = 0.033 (F = 4.151, df = 2,18), and observed
statistical power was 65.6%, with results trending toward statistical
significance. Comparing trait anxiety at baseline with 2-month
follow-up yielded an effect size of 1.1. However, only three of
eight experimental dose subjects dropped lower than the threshold
value of 40 after the intervention. In contrast, all active placebo
subjects experienced increases in trait anxiety. Figure 2 shows a clear
linear relationship between visit and mean trait anxiety for the ex-
perimental dose group, whereas no such relationship exists for the
active placebo group. Comparison of 2-month and 12-month follow-up
results in the subjects who received 200 Kg of LSD in either the
blinded sessions or the open-label crossover indicate that the benefits
were sustained over time. The mean difference varied only by 0.667
between these assessments, and no significant difference was found
with p = 0.825 (two tailed).
For STAI state, Mauchly’s Test of Sphericity was not signifi-
cant ( p = 0.813), and sphericity was assumed. No significant dif-
ference was found between the groups at baseline ( p = 0.563). The
visit  group interaction testing for differences between the groups
produced p = 0.021 (F = 4.846, df = 2,18), and observed statistical
power was 72.7%. Even controlling for multiplicity, the reductions in
state anxiety were statistically significant 2 months after two exper-
imental sessions of LSD-assisted psychotherapy. Comparing state
anxiety at baseline with 2-month follow-up yielded an effect size of
1.2. However, only three of eight experimental dose subjects dropped
lower than the diagnostic cutoff of 40 after the intervention. In con-
trast, two active placebo subjects experienced increases in state anxi-
ety. Figure 2 shows a clear linear relationship between visit and state
anxiety for the experimental dose group, whereas no such relation-
ship exists for the active placebo group. Comparison of 2-month and
12-month follow-up results in the subjects who received 200 Kg of
LSD in either the blinded sessions or the open-label crossover in-
dicates that the benefits were sustained over time. The mean difference
varied only by 1.00 between these assessments, and no significant
difference was found with p = 0.531 (two tailed).
Changes in secondary outcome measures were not analyzed
for statistical significance because of concerns about multiplicity.
However, the results obtained from these measures were, overall,
quite supportive of the STAI results (Table 2). Global health scores
from the EORTC-QLQ increased from a mean (SD) of 37.4 (10.0)
at baseline to 50.0 (14.9) after treatment with two sessions of 200 Kg
of LSD, whereas mean scores decreased from 44.3 (12.7) to 36.0
(12.8) in the active placebo group. Scores increased on average in the
subjects who received 200 Kg of LSD treatments and continued to
12-month follow-up, indicating that most of the subjects receiving
the experimental dose were able to attain and maintain comparable
quality of life with the general European population by participating in
this study (Scott et al., 2008).
The SCL-90-R is a widely used measure of overall psycho-
logical problems and psychopathology. Global Severity Index (GSI)
scores from the SCL-90-R decreased from a mean (SD) T-score of
TABLE 2. Study Outcomes
Baseline
Blinded 2-Month
Follow-up
Crossover 2-Month
Follow-up
12-Month
Follow-up
Experimental
Dose V6
Active Placebo
Dose V6
Experimental
Dose V14
Active Placebo
Dose V14
Experimental
Dose V23
Any Subject Receiving
Experimental Dose
n = 8 n = 3 n = 8 n = 3 n = 3 n = 9
Measure Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Primary
STAI-state 53.1 4.7 47.7 7.7 41.5* 3.2 51.7 5.3 36.0 12.5 36.1 8.3
STAI-trait 53.2 4.3 43.3 7.0 45.2 3.7 49.0 6.1 36.0 8.5 41.1 10.8
Secondary
QLQ-30 global 37.4 10.0 44.3 12.7 50.0 14.9 36.0 12.8 52.7 21.1 54.4 18.2
SCL-90-R GSI 69.6 6.7 66.0 15.1 60.2 7.2 67.7 10.2 57.3 15.0 Not done
SCL-90-R PSDI 62.1 5.5 57.7 5.5 53.4 8.0 62.3 5.5 54.7 14.6 Not done
SCL-90-R PST 67.9 6.7 64.0 13.4 61.2 8.0 66.0 13.1 56.7 14.8 Not done
HADS-A 11.7 3.4 11.3 2.1 8.1 3.2 10.7 3.0 7.0 2.6 7.6 4.5
HADS-D 10.0 4.5 9.3 4.2 7.5 3.3 8.7 2.9 4.7 4.0 7.6 4.7
Primary and secondary measures.
SCL-90-R scales: GSI, PSDI, and PST; HADS scales: anxiety (A) and depression (D).
*Statistically significant difference between test conditions after adjusting for multiplicity (p = 0.021, F = 4.846, df = 2,18).
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69.6 (6.7) at baseline to 60.2 (7.2) in the experimental dose group
whereas increasing from 66.0 (15.1) to 67.7 (10.2) in the active
placebo group. The active placebo group experienced an improve-
ment comparable with the full-dose group after receiving the exper-
imental dose in the open-label crossover, with mean (SD) T-scores
dropping to 57.3 (15.0). Both Positive Symptom Distress Index
(PSDI) and Positive Symptom Total (PST) scores from the SCL-90-R
mirrored these improvements, indicating that overall psychopathol-
ogy improved in this subject sample 2 months after treatment.
The HADS results were also generally supportive of overall
improvements in this subject sample. The experimental dose group
mean (SD) anxiety scores decreased from 11.7 (3.4) to 8.1 (3.2) after
two sessions, whereas the active placebo group anxiety scores decreased
only from 11.3 (2.1) to 10.7 (3.0). The active placebo subjects who
continued to the crossover experienced an even greater decline lower
than the diagnostic cutoff for anxiety to 7.0 (2.6). All subjects who
received the experimental dose were lower than the diagnostic cutoff
at the 12-month follow-up, with a mean (SD) of 7.6 (4.5). The de-
pression results also mirrored the anxiety results. Overall, the second-
ary outcome measures of the study were useful in supporting the results
of the primary outcome measure.
For all 24 blinded sessions, all participants correctly guessed
the dose of LSD that was administered, and both therapists guessed
incorrectly in one active placebo session. The therapists were ‘‘very
certain’’ in 22 sessions, ‘‘certain’’ in 1 session, and ‘‘somewhat certain’’
in 1 session. The participants were ‘‘very certain’’ in 20 sessions,
‘‘certain’’ in 1 session, ‘‘somewhat certain’’ in 2 sessions, and ‘‘not at all
certain’’ in one session. This indicates that the 20-Kg dose was too low
to achieve successful uncertainty about the dose.
Safety
Neither the experimental dose (200 Kg of LSD) nor the active
placebo (20 Kg of LSD) produced any drug-related severe adverse
events, that is, no panic reaction, no suicidal crisis or psychotic state,
and no medical or psychiatric emergencies requiring hospitalization.
Related AEs (Table 3) included both positive and negative effects
commonly associated with LSD. The experimental dose subjects
experienced more types of AEs (n = 18) than the active placebo
subjects (n = 8). In general, AEs were reported more frequently and
with increased intensity in the experimental dose sessions. Interest-
ingly, fewer reports of anxiety were received during experimental
sessions with 200 Kg (22.7%) than with active placebo (50%), and the
mean intensity of anxiety was comparable between the groups. How-
ever, the subjects reported experiencing mild-to-moderate emo-
tional distress similarly in experimental dose sessions (36.4%) and
active placebo sessions (33.3%). Most AEs resolved when drug
effects diminished. Only six reports of mild related AEs (illusions,
feeling cold or abnormal, and some emotional distress) persisted
TABLE 3. Related AEs
Related AEs
Day of Session Day of Session Day After Session Day After Session
Experimental Dose Active Placebo Dose Experimental Dose Active Placebo Dose
Sessions: 22 Sessions: 6 Sessions: 22 Sessions: 6
Subjects: 8 Subjects: 3 Subjects: 8 Subjects: 3
n Prevalence
Mean
Severity n Prevalence
Mean
Severity n Prevalence
Mean
Severity n Prevalence
Mean
Severity
Affect lability 3 13.6% 1.3 0 0% 0.0 0 0% 0.0 0 0% 0.0
Anger 1 4.5% 2.0 2 33.3% 1.5 0 0% 0.0 0 0% 0.0
Anxiety 5 22.7% 2.2 3 50% 2.3 0 0% 0.0 0 0% 0.0
Bradyphrenia 1 4.5% 1.0 0 0% 0.0 0 0% 0.0 0 0% 0.0
Depersonalization 1 4.5% 1.0 0 0% 0.0 0 0% 0.0 0 0% 0.0
Derealization 2 9.1% 2.0 0 0% 0.0 0 0% 0.0 0 0% 0.0
Emotional
distress
8 36.4% 1.9 2 33.3% 1.5 2 9.1% 1.0 0 0% 0.0
Euphoric mood 1 4.5% 2.0 0 0% 0.0 0 0% 0.0 0 0% 0.0
Feeling abnormal 9 40.9% 2.3 2 33.3% 1.0 1 4.5% 1.0 0 0% 0.0
Feeling cold 10 45.4% 2.0 0 0% 0.0 2 9.1% 1.5 0 0% 0.0
Feeling
of relaxation
1 4.5% 2.0 0 0% 0.0 0 0% 0.0 0 0% 0.0
Gait disturbance 7 31.8% 1.3 0 0% 0.0 0 0% 0.0 0 0% 0.0
Hallucination 1 4.5% 1.0 0 0% 0.0 0 0% 0.0 0 0% 0.0
Hyperhidrosis 3 13.6 % 1.3 0 0% 0.0 0 0% 0.0 0 0% 0.0
Secondary
hypertension
1 4.5% 1.0 0 0% 0.0 0 0% 0.0 0 0% 0.0
Illusion 16 72.7% 1.8 1 16.7% 1.0 1 4.5% 1.0 0 0% 0.0
Mydriasis 4 18.2% 1.5 0 0% 0.0 0 0% 0.0 0 0% 0.0
Perseveration 1 4.5% 2.0 0 0% 0.0 0 0% 0.0 0 0% 0.0
Tachyphrenia 0 0% 0.0 1 16.7% 1.0 0 0% 0.0 0 0% 0.0
Thinking
abnormal
2 9.1% 1.5 2 33.3% 1.5 0 0% 0.0 0 0% 0.0
Vision blurred 0 0% 0.0 1 16.7% 1.0 0 0% 0.0 0 0% 0.0
n indicates number of spontaneous reports; %, n in percentage of sessions.
Severity assigned by investigator based on impairment of daily function: 1, mild; 2, moderate; 3, severe.
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until the next day. No flashback phenomena or other prolonged
effects were observed.
Concomitant Medication
During the study, two participants (both experimental dose)
received concomitant selective serotonin reuptake inhibitor (SSRI)
treatment for depression and tapered off of these medications five
half-lives before each experimental session because SSRIs may at-
tenuate the effects of the serotonergically active experimental drug
(Bonson et al., 1996). Three participants received benzodiazepines
(two experimental dose and one active placebo) as needed. Three
participants received pain medication during the study, only one of
which was required as rescue medication for a treatment-emergent AE.
Acetaminophen was required for this participant for a moderate head-
ache the day after an experimental dose session.
Physiological Measures
Physiological measures were recorded for all participants
during experimental sessions. Consistent with the previous findings
(Kornetsky, 1957; Sokoloff et al., 1957), LSD did not significantly
alter blood pressure or heart rate (Table 4).
DISCUSSION
All research with LSD-assisted psychotherapy in the 1950s
and the 1960s came to a halt by the early 1970s. Our study, the first
in more than 40 years to evaluate safety and efficacy of LSD as an
adjunct to psychotherapy, was conducted in participants with anxiety
after being diagnosed with a life-threatening illness. In contrast to the
shortcomings of older studies, we used a controlled, randomized, and
blinded study design to meet contemporary research standards. LSD
was given in a psychotherapeutic context to facilitate a deep psy-
chedelic state, allowing the participant to encounter his/her own inner
realities during an emotionally intensified dream-like ‘‘journey.’’
In our study, using appropriate inclusion/exclusion criteria, de-
tailed participant preparation, and a carefully supervised experience in a
supportive psychotherapeutic setting, psychological side effects were
mild and limited. There were no AEs often attributed to LSD such as
prolonged anxiety (‘‘bad trip’’) or lasting psychotic or perceptional
disorders (flashbacks). Congruent with studies in the past (Hintzen and
Passie, 2010), the few mild somatic effects of LSD such as changes in
heart rate and blood pressure were of no clinical significance.
The primary outcome variable in this study was of the STAI
anxiety measure. Patients with life-threatening illnesses confront an
existential threat from shortened life expectancy that often causes
periods of suffering, pain, and anxiety. Congruent with earlier studies
(Pahnke et al., 1970), the results in the experimental dose group show
a significant reduction in state anxiety, as experienced on a daily
basis. Furthermore, the more stable personality-inherent feature of
anxiety proneness (trait anxiety) showed a strong trend toward re-
duction. Trait anxiety is not expected to be altered by short-term
psychotherapy (Spielberger et al., 1970), but a comparable finding
was reported in recent research with psilocybin in cancer patients that
reported significant reductions of trait anxiety (although without
correction for multiplicity) but not state anxiety (Grob et al., 2011).
Therefore, this trait change may be supported by neurobiological
effects of adjunctive use of LSD, which was originally introduced for
deepening and accelerating psychotherapeutic processing (Abramson,
1967) and, in some studies, was shown to alter personality traits
(MacLean et al., 2011; McGlothlin et al., 1967; Savage et al., 1966).
In this study, the experimental dose reduced anxiety when
administered in either the blinded treatment or the open-label cross-
over for the active placebo subjects. These results were stable over
time as shown by the 12-month follow-up. Eleven of 12 participants
treated were LSD-naive. A moderate dose (200 Kg) provided a psy-
chologically manageable first LSD experience. Most of the partici-
pants stated a preference for more than two LSD sessions and a
longer treatment period. The results demonstrated a decrease in STAI
scores most prominently after the second LSD session, suggesting
that at least two LSD sessions are needed to demonstrate these ef-
fects. A longer treatment period with additional LSD sessions and
larger doses may be indicated (Gasser, 1996).
Limitations of the Study
As a pilot study, this study had limited sample size, which
reduced precision in effect size estimates and significance testing.
The sample size selected was sufficient for a study primarily focused
on safety and feasibility. The imperfect blinding also limits the va-
lidity of the results. The problem of the double blind in studies with
pharmacologically active substances is a well-known methodological
challenge (Mogar, 1967; Salzman, 1969). LSD is a potent psycho-
active drug, and participants and therapists are likely to detect
whether an experimental dose or an inactive placebo or active pla-
cebo of very low dose of LSD was administered. Although using a
slightly higher LSD dose in the comparator group can increase
blinding, it can also increase efficacy of the comparator, compromising
the estimates of effect size. Given the safety of the moderate experi-
mental dose, results might have been improved with a larger dose of
250 Kg. Other limitations exist in treating participants with grave so-
matic diseases because the course of the somatic illness (e.g., wors-
ening or improving) may substantially impact psychological parameters
independent of the therapeutic intervention and contribute to missing
data. The quality of life questionnaire (EORTC-QLQ), which was cho-
sen as a secondary outcome measure, focuses extensively on physical
aspects and was insufficient for evaluating long-term psychological
changes. Future studies should include a quality of life measure that
focuses on psychological well-being more so than physical aspects of
quality of life in this population.
CONCLUSIONS
This pilot study in participants with anxiety associated with
the diagnosis of a life-threatening illness has demonstrated safety in
22 psychotherapy sessions assisted by 200 Kg of LSD with no drug-
related severe adverse events. Group comparison results support posi-
tive trends in reduction of anxiety after two sessions of LSD-assisted
TABLE 4. Physiological Measurements
Time
Post-LSD (hour)
Experimental Dose Group (n = 8) Active Placebo Group (n = 4)
HR (bpm) SBP (mm Hg) DBP (mm Hg) HR (bpm) SBP (mm Hg) DBP (mm Hg)
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
0 74.8 10.0 130.3 13.5 80.0 9.3 82.0 17.1 136.7 7.5 85.0 7.1
4 73.0 9.9 129.1 16.3 80.3 10.2 78.0 18.4 134.7 13.9 87.0 4.7
8 73.3 12.5 126.3 9.0 77.5 9.10 77.3 15.5 137.5 7.6 87.5 4.2
bpm indicates beats per minute; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure.
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psychotherapy, with effect size estimates in the range of 1.1 to 1.2.
In view of promising historical studies with adjunctive LSD treat-
ment in this population and a recent promising study using psilocybin
(Grob et al., 2011), as well as the urgent need for more effective treat-
ments of anxiety in these participants, further study is warranted into
the potential of LSD-assisted psychotherapy.
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